A detailed history of Choate Investment Advisors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Choate Investment Advisors holds 4,312 shares of VRTX stock, worth $1.76 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
4,312
Previous 4,613 6.53%
Holding current value
$1.76 Million
Previous $2.16 Million 7.26%
% of portfolio
0.05%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $138,460 - $152,239
-301 Reduced 6.53%
4,312 $2.01 Million
Q2 2024

Aug 08, 2024

SELL
$392.81 - $485.53 $173,622 - $214,604
-442 Reduced 8.74%
4,613 $2.16 Million
Q1 2024

May 07, 2024

SELL
$407.69 - $446.08 $4,076 - $4,460
-10 Reduced 0.2%
5,055 $2.11 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $552,573 - $661,605
1,611 Added 46.64%
5,065 $2.06 Million
Q3 2023

Oct 30, 2023

BUY
$338.18 - $362.46 $382,819 - $410,304
1,132 Added 48.75%
3,454 $1.2 Million
Q2 2023

Aug 01, 2023

BUY
$314.42 - $351.91 $80,805 - $90,440
257 Added 12.45%
2,322 $817,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $32,290 - $36,327
113 Added 5.79%
2,065 $596,000
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $152,489 - $189,864
649 Added 49.81%
1,952 $550,000
Q1 2022

Apr 29, 2022

BUY
$221.42 - $260.97 $14,170 - $16,702
64 Added 5.17%
1,303 $340,000
Q3 2021

Nov 04, 2021

SELL
$181.39 - $202.99 $147,288 - $164,827
-812 Reduced 39.59%
1,239 $225,000
Q2 2021

Jul 30, 2021

BUY
$187.49 - $221.1 $150,929 - $177,985
805 Added 64.61%
2,051 $414,000
Q1 2021

May 07, 2021

BUY
$207.02 - $241.31 $257,946 - $300,672
1,246 New
1,246 $268,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Choate Investment Advisors Portfolio

Follow Choate Investment Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Choate Investment Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Choate Investment Advisors with notifications on news.